Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Location status: Recruiting
Location contact
Jianping Li, MD
PRINCIPAL_INVESTIGATOR
Yuxi Li, MD
CONTACT
Yuxi Li, MD
SUB_INVESTIGATOR
NCT Number: NCT06447740
Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical.
The overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients.
With the 'all comers' design, participants met the inclusive/exclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is <0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100034, China
Location status: Recruiting
Jianping Li, MD
PRINCIPAL_INVESTIGATOR
Yuxi Li, MD
CONTACT
Yuxi Li, MD
SUB_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
Renal FFR will be measured based on SOP
Renal artery stenting will be implanted based on the protocol
Time frame: From baseline to 3 months post-procedure
Time frame: From baseline to 3 months post-procedure
Change in the composite index of antihypertensive drugs. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)
Time frame: From baseline to 3 months post-procedure
Time frame: From baseline to 3 months post-procedure
Time frame: From baseline to 3 months post-procedure
Time frame: From baseline to 3 months post-procedure
Time frame: From baseline to 1 year post-procedure
Change in the composite index of antihypertensive drugs to reach target blood pressure. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)
Time frame: From baseline to 6 months, 1 year post-procedure
Time frame: From baseline to 1 year post-procedure
Time frame: From baseline to 1 year post-procedure
Time frame: From baseline to 1 year post-procedure
Based on universal definition of acute myocardial infarction
Time frame: From baseline to 1 year post-procedure
Based on medical records under outcome committee's judge
Time frame: From baseline to 1 year post-procedure
Based on medical records under outcome committee's judge
Time frame: From baseline to 1 year post-procedure
Contact information is provided by the study sponsor or research team.
Peking University First Hospital
Other
Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone In Atherosclerosis Renal-vascular Hypertension Patients: a Multicenter Randomized Trial
Acronym: FAIR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07111442
Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial
Beijing, Beijing Municipality, China
View Trial DetailsNCT05834803
Cardiovascular Diseases, Female Urogenital Diseases
Aarhus N, Denmark
View Trial DetailsNCT06913530
Arterial Occlusive Diseases, Cardiovascular Diseases
View Trial DetailsNCT06664255
Adrenal Gland Diseases, Adrenocortical Hyperfunction
View Trial Details